glp 1 joint inflammation Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling Full article: GLP-1 agonists: a

Type 2 diabetes mellitus (T2DM) is a widespread metabolic disorder characterized by insulin resistance and pancreatic -cell dysfunction, posing a substantial global health challenge

Why Doctor's Blend GLP-1

While evidence supports behavior modification, compounded GLP-1 medications may address metabolic factors that behavioral interventions alone cannot target

Among non-diabetic patients without chronic kidney disease (CKD), there was a minimal increase of 0.01 mg/dL to 0.02 mg/dL in serum creatinine in the months following initiation of semaglutide, liraglutide, or tirzepatide

The STEP 1 trial showed up to 45% of weight lost on semaglutide was lean mass

Meanwhile, patients are looking for solutions to any number of conditions with the hope that new treatments can provide more options or, perhaps, better outcomes